Centessa Pharma Taps John Crowley, as CFO, Effective June 10

6/10/24 7:20:39 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CNTA alert in real time by email

Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024.

Get the next $CNTA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CNTA

Date	Price Target	Rating	Analyst
9/20/2024	$11.00 → $26.00	Equal-Weight → Overweight	Morgan Stanley
9/19/2024	$33.00	Buy	B. Riley Securities
7/18/2024	$14.00	Outperform	Oppenheimer
11/15/2023	$4.00 → $11.00	Hold → Buy	Jefferies
10/26/2023	$4.00 → $8.00	Underweight → Equal-Weight	Morgan Stanley
6/21/2023		Outperform	Evercore ISI
6/12/2023	$9.00	Buy	Guggenheim
3/17/2023	$6.00	Outperform	SVB Securities

More analyst ratings

$CNTA
Leadership Updates

Live Leadership Updates

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen
6/10/24 7:00:00 AM ET
$CNTA
Biotechnology: Pharmaceutical Preparations
Health Care
Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody® technology platform. "We a
10/3/23 8:00:00 AM ET
$CNTA
Biotechnology: Pharmaceutical Preparations
Health Care
Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director
Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.
3/23/23 4:30:00 PM ET
$CLVT
$CNTA
EDP Services
Technology
Biotechnology: Pharmaceutical Preparations
Health Care

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in acutely sleep-deprived healthy volunteers that further support best-in-class potential of ORX750 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH); Presentation of Phase 1 data planned for medical congress in Q2 2025Initiated Phase 2a clinical study of ORX750 in patients with NT1, NT2 and IH; Phase 2a data across all three indications expected in 2025 with first-in-class potential in NT2 and IHAdvancing ORX142 in IND-enabling studies for treatment of neurological, neurodegenerative, and psychiatric disorders; Clinical data in healthy
11/12/24 7:00:15 AM ET
$CNTA
Biotechnology: Pharmaceutical Preparations
Health Care
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim Healthcare Innovation Conference Date: November 13, 2024Location: Boston, MAFireside Chat: 9:00 AM ET Event: Jefferies London Healthcare Conference Date: November 19, 2024Location: London, UKFireside Chat: 1:30 PM GMT Event: 7th Annual Evercore HealthCONx ConferenceDate: December 5, 2024Location: Miami, FLFireside Chat: 10:00 AM ET Access to the
11/4/24 7:30:00 AM ET
$CNTA
Biotechnology: Pharmaceutical Preparations
Health Care
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders BOSTON and LONDON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today shared new preclinical data from non-human primate (NHP) studies of ORX142, an investigational, novel, orexin receptor 2 (OX2R) agonist being advanced for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodeg
9/26/24 6:00:31 AM ET
$CNTA
Biotechnology: Pharmaceutical Preparations
Health Care

$CNTA
Financials

Live finance-specific insights

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentation at American Society of Hematology (ASH) Annual Meeting in December 2023 ORX750: Preclinical data supporting potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders presented at World Sleep Congress; Advancing in IND-enabling studies; Clinical proof of concept data planned for 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA
11/13/23 4:05:10 PM ET
$CNTA
Biotechnology: Pharmaceutical Preparations
Health Care
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment of solid tumors IND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; Announces ORX750 preclinical data to be presented at World Sleep Congress in October 2023 Nominates second LockBody candidate, LB206, a conditionally bivalent PD-L1xCD3 bispecific monoclonal antibody BOSTON and LONDON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceuti
8/14/23 7:00:30 AM ET
$CNTA
Biotechnology: Pharmaceutical Preparations
Health Care
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational feeder study Dosing subjects in ongoing Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody® to treat solid tumorsConducting IND enabling activities for ORX750, an orally administered, selective orexin receptor 2 (OX2R) agonist, with the potential to be a best-in-class therapy to treat narcolepsy and other sleep disorders; ORX750 profile to be presented at scientific meeting in 2023 BOSTON and LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals
5/12/23 7:00:06 AM ET
$CNTA
Biotechnology: Pharmaceutical Preparations
Health Care

Centessa Pharma Taps John Crowley, as CFO, Effective June 10

Chat with this insight

Recent Analyst Ratings for $CNTA

$CNTA SEC Filings

Centessa Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Centessa Pharmaceuticals plc

SEC Form 144 filed by Centessa Pharmaceuticals plc

$CNTA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc (Amendment)

$CNTA Market Insights

Live Market Insights

Oppenheimer Initiates Coverage On Centessa Pharmaceuticals with Outperform Rating, Announces Price Target of $14

Morgan Stanley Maintains Equal-Weight on Centessa Pharmaceuticals, Raises Price Target to $11